Starks Daniel J buys $927K of ABT

Director Starks Daniel J purchased 10,000 shares of Abbott Laboratories (ABT) common stock at $92.65 per share for a total of $926,537 on April 27, 2026, per a Form 4 filed with the U.S. Securities and Exchange Commission on April 28, 2026.

The Transaction

The April 28, 2026, Form 4 also disclosed two additional equity transactions for Starks, a company director: 2,286 no-cost restricted stock unit awards, and 7,105 open-market shares purchased at $91.86 per share for $652,665. ABT has a current market capitalization of $157.5B, per available public data.

Insider Context

Over the 90-day window ending April 29, 2026, only two Abbott insiders have executed discretionary open-market share purchases: Starks, whose 10,000-share buy marked his second open-market transaction that day, and Executive Vice President Moreland Mary K, who bought 5,314 shares on April 29, 2026, at $94.41 per share for $501,695. All other recent insider SEC Form 4 filings for directors including Conroy Kevin T, Stratton John G, and O’Grady Michael consisted solely of no-cost equity awards, with no cash outlay. No insider selling has been disclosed in ABT Form 4 filings during this period.

Cross-Reference to Institutional and Analyst Data

As of December 31, 2025, ABT had 3,310 institutional holders, a 68 quarter-over-quarter increase, with institutions holding 81.7% of the company’s float and aggregate total holdings valued at $178.9B. Institutional positioning has been net bullish, with 321 new funds entering positions, 1,468 increasing existing holdings, and only 1,347 reducing positions in the latest 13F filing. Analyst ratings have remained static since January 2026, with 6 Strong Buy, 16 Buy, and 7 Hold assignments, no Sell or Strong Sell ratings. The purchase coincided with Abbott’s April 28, 2026, FDA and CE Mark clearance for its Ultreon™ 3.0 AI-powered coronary imaging platform, per public PRNewswire filings. Additionally, ABT beat both EPS and revenue estimates in its April 16, 2026, quarterly report, posting EPS of $1.15 vs. consensus $1.14 and revenue of $11.164B vs. consensus $10.9996B.

What This Transaction Does NOT Signal

First, this open-market purchase does not imply a formal company earnings guidance update, as Abbott’s next quarterly earnings report is scheduled for July 16, 2026, and no 8-K guidance filing has been submitted as of the Form 4 filing date. Second, it does not reflect universal insider sentiment: only two insiders have made open-market purchases in the last 90 days, while most recent insider activity consisted of no-cost equity awards, not discretionary cash investments. Third, this transaction does not correlate directly to near-term share price movement, as ABT’s current trading price of $90.13 is 2.7% below the per-share purchase price of Starks’ 10,000-share open-market buy.